Thai Nakorn Patana
Thai Nakorn Patana (SET: TNP) is a Thailand-domestic-focused listed pharmaceutical manufacturer. FY2024 consolidated revenue approximately THB 3B. Product portfolio covers generics, OTC, hospital products; family-controlled with GMP-compliant manufacturing in Samut Prakan. Smaller scale than Mega Lifesciences but purer Thailand-domestic play without Mega's regional-distribution exposure. Primary channels: hospital, retail pharmacy, wholesaler network.
Snapshot
Headline numbers a buyer checks first.
FY2024 revenue
~THB 3B
FY2024
Steady domestic growth; ~5-7% CAGR 2019-2024
Net profit margin
~8-12%
FY2024
Generic manufacturer; below Mega's branded margins
Ticker
SET: TNP
Listed 2019
IPO via Mai board initially, moved to SET main board
Products
Generics, OTC, hospital products
FY2024
300+ SKUs across key therapeutic categories
Manufacturing
Samut Prakan, GMP-certified
FY2024
Founded
1971
Historical
What this company actually does
TNP manufactures, distributes generic prescription drugs, OTC products, and hospital supplies to Thai hospitals, retail pharmacies, and wholesalers. Core product categories include cardiovascular, antibiotic, pain, inflammation, gastrointestinal, and topical preparations. Family-controlled with professional management; listed on SET in 2019 via IPO. Smaller scale than MEGA, GPO, Siam Pharmaceutical but operationally disciplined.[]
Strategic position: TNP is the Thailand-domestic-focused listed pharma option at smaller scale. Distinct from Mega (emerging-market distribution) in being a pure Thai domestic play. Competitive pressure: ~500 private manufacturers on the low-cost end, MEGA, GPO, Siam Pharma at larger scale, MNC originator subsidiaries on specialty, patented products. TNP defensibility relies on hospital, retail-pharmacy relationships, product-portfolio discipline rather than scale or novel-product innovation.[]
Business model and competitive position
Thai Nakorn Patana is the smallest SET-listed Thai pharma manufacturer — understanding the niche matters.
Pure domestic focus
No regional-distribution exposure — a cleaner Thai signal
Unlike Mega Lifesciences (which derives 80%+ of revenue from ASEAN-wide OTC brand distribution), TNP's revenues are almost entirely Thailand-domestic. This makes TNP a purer proxy for Thai domestic pharmaceutical demand — hospital procurement cycles, UCS reimbursement changes, and retail-pharmacy growth trends map directly to TNP's top line.[]
Listed since 2019
SET-listed with public disclosure
TNP's 2019 SET listing provides quarterly financial disclosures unavailable for private competitors such as Siam Pharmaceutical. The 56-1 annual report details revenue by product category, hospital vs retail channel split, and gross-margin progression — making TNP one of the more transparent mid-size domestic manufacturers.[]
Channel
Hospital direct is 60-65% of revenue
Hospital direct supply (government hospital tenders under UCS and social security schemes, plus private hospital procurement) accounts for an estimated 60-65% of TNP revenue. Retail pharmacy and wholesale make up the remainder. Hospital dominance means NLEM inclusion and MoPH procurement calendar are the key revenue cycle drivers.[]
Manufacturing
Samut Prakan GMP plant; capacity headroom
TNP's manufacturing facility in Samut Prakan is GMP-certified to Thai FDA standards with PIC/S harmonisation pathway. The facility has headroom above FY2024 production volumes — capacity utilisation likely 60-70%. This provides ability to grow revenue without large capex investment, supporting margin expansion potential.[]
TNP therapeutic category coverage
Key product categories and TNP's approximate contribution.
Cardiovascular
Example products
Antihypertensives, statins (generics)
Primary channel
Hospital direct, UCS
Key competition
GPO, Siam Pharma, imports
Antibiotics
Example products
Amoxicillin, cephalosporins (generics)
Primary channel
Hospital, retail pharmacy
Key competition
GPO, ~500 private manufacturers
Analgesics, anti-inflammatory
Example products
Paracetamol, NSAIDs (OTC)
Primary channel
Retail pharmacy, wholesale
Key competition
Thai Nippon, Siam Pharma, imports
Gastrointestinal
Example products
Antacids, antiemetics, laxatives
Primary channel
Retail pharmacy, hospital
Key competition
Private manufacturers, GPO
Topical preparations
Example products
Creams, ointments
Primary channel
Retail pharmacy
Key competition
Private manufacturers, imports
| Therapeutic category | Example products | Primary channel | Key competition |
|---|---|---|---|
| Cardiovascular | Antihypertensives, statins (generics) | Hospital direct, UCS | GPO, Siam Pharma, imports |
| Antibiotics | Amoxicillin, cephalosporins (generics) | Hospital, retail pharmacy | GPO, ~500 private manufacturers |
| Analgesics, anti-inflammatory | Paracetamol, NSAIDs (OTC) | Retail pharmacy, wholesale | Thai Nippon, Siam Pharma, imports |
| Gastrointestinal | Antacids, antiemetics, laxatives | Retail pharmacy, hospital | Private manufacturers, GPO |
| Topical preparations | Creams, ointments | Retail pharmacy | Private manufacturers, imports |
Business model and competitive position
Thai Nakorn Patana is the smallest SET-listed Thai pharma manufacturer — understanding the niche matters.
Pure domestic focus
No regional-distribution exposure — a cleaner Thai signal
Unlike Mega Lifesciences (which derives 80%+ of revenue from ASEAN-wide OTC brand distribution), TNP's revenues are almost entirely Thailand-domestic. This makes TNP a purer proxy for Thai domestic pharmaceutical demand — hospital procurement cycles, UCS reimbursement changes, and retail-pharmacy growth trends map directly to TNP's top line.[]
Listed since 2019
SET-listed with public disclosure
TNP's 2019 SET listing provides quarterly financial disclosures unavailable for private competitors such as Siam Pharmaceutical. The 56-1 annual report details revenue by product category, hospital vs retail channel split, and gross-margin progression — making TNP one of the more transparent mid-size domestic manufacturers.[]
Channel
Hospital direct is 60-65% of revenue
Hospital direct supply (government hospital tenders under UCS and social security schemes, plus private hospital procurement) accounts for an estimated 60-65% of TNP revenue. Retail pharmacy and wholesale make up the remainder. Hospital dominance means NLEM inclusion and MoPH procurement calendar are the key revenue cycle drivers.[]
Manufacturing
Samut Prakan GMP plant; capacity headroom
TNP's manufacturing facility in Samut Prakan is GMP-certified to Thai FDA standards with PIC/S harmonisation pathway. The facility has headroom above FY2024 production volumes — capacity utilisation likely 60-70%. This provides ability to grow revenue without large capex investment, supporting margin expansion potential.[]
TNP therapeutic category coverage
Key product categories and TNP's approximate contribution.
Cardiovascular
Example products
Antihypertensives, statins (generics)
Primary channel
Hospital direct, UCS
Key competition
GPO, Siam Pharma, imports
Antibiotics
Example products
Amoxicillin, cephalosporins (generics)
Primary channel
Hospital, retail pharmacy
Key competition
GPO, ~500 private manufacturers
Analgesics, anti-inflammatory
Example products
Paracetamol, NSAIDs (OTC)
Primary channel
Retail pharmacy, wholesale
Key competition
Thai Nippon, Siam Pharma, imports
Gastrointestinal
Example products
Antacids, antiemetics, laxatives
Primary channel
Retail pharmacy, hospital
Key competition
Private manufacturers, GPO
Topical preparations
Example products
Creams, ointments
Primary channel
Retail pharmacy
Key competition
Private manufacturers, imports
| Therapeutic category | Example products | Primary channel | Key competition |
|---|---|---|---|
| Cardiovascular | Antihypertensives, statins (generics) | Hospital direct, UCS | GPO, Siam Pharma, imports |
| Antibiotics | Amoxicillin, cephalosporins (generics) | Hospital, retail pharmacy | GPO, ~500 private manufacturers |
| Analgesics, anti-inflammatory | Paracetamol, NSAIDs (OTC) | Retail pharmacy, wholesale | Thai Nippon, Siam Pharma, imports |
| Gastrointestinal | Antacids, antiemetics, laxatives | Retail pharmacy, hospital | Private manufacturers, GPO |
| Topical preparations | Creams, ointments | Retail pharmacy | Private manufacturers, imports |
Watchpoints
Thai domestic market-share trajectory
Hospital, retail-pharmacy channel retention.
NLEM, UCS procurement wins
State procurement, public-hospital tender success.
Product-portfolio expansion
New-product development, therapeutic-category depth.
Scale vs margin trade-off
Smaller scale; margin-per-revenue vs larger peers.
Related Market profiles
Peers, parents, partners, agencies, and other Pharmaceuticals actors.
Competitor
Mega Lifesciences
Larger listed peer; Mega emerging-market-tilted vs TNP domestic.
Open Market profile →
Competitor
Siam Pharmaceutical
Leading private Thai generics manufacturer.
Open Market profile →
Competitor
Government Pharmaceutical Organisation (GPO)
State generics manufacturer.
Open Market profile →
Sector peer
Government Pharmaceutical Organization (GPO)
Thai state pharmaceutical manufacturer; produces essential medicines, vaccines, and APIs under MoPH mandate for public-health security.
Open Market profile →
Sources + data provenance
Every filing, filing-adjacent register, or trusted industry source cited in this profile.
Thai Nakorn Patana — TNP (SET: TNP) FY2024 Form 56-1 One Report
| Source | Publisher | Grade | As of |
|---|---|---|---|
| Thai Nakorn Patana — TNP (SET: TNP) FY2024 Form 56-1 One Report | Thai Nakorn Patana PCL | Primary | 2025-03-31 |
Reports featuring this profile
Thailand Pharmaceuticals Market Intelligence
Listed Thai generics, OTC, hospital products; FY2024 revenue ~THB 3B; Thailand-domestic focus.
Open report →
Sits alongside 7 other Atlas profilesThailand Pharma Generic vs Branded Deep Dive
Thai Nakorn Patana generic, OTC.
Open report →
Sits alongside 7 other Atlas profilesRelated Market profiles
competitor
Mega Lifesciences
Largest Thai-listed pharma by revenue; emerging-market distribution franchise; FY2024 revenue ~THB 16B.
competitor
Siam Pharmaceutical
Leading private Thai generics, OTC manufacturer since 1939; hospital, retail, wholesale channel depth.
competitor
Government Pharmaceutical Organisation (GPO)
Thai state pharmaceutical manufacturer; generics, HIV ARV, biosimilar, Strategic Stockpile; FY2024 revenue ~THB 16B.